Department of Basic and Translational Oncology and Hematology

Research output

Research output per year 2017 2018 2019 2021 2022 2023 2024 2024

• 47 Journal article
• 16 Conference contribution to journal
• 13 Review article
• 7 Other publication (not peer-reviewed)
• 15 More
  • 5 Poster at a conference
  • 4 Oral presentation at a conference
  • 3 Invited talk/keynote at a conference
  • 2 Editorial
  • 1 Letter/short communication

Research output per year

Research output per year

Search results

• 2021

  Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity

  Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Fan, F., Zwickl-Traxler, E., Stoiber, D., Bakiri, L., Wagner, E. F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021, In: Blood. 138, Supplement 1, 2644.

  Research output: Journal article (peer-reviewed) › Journal article

  • Trametinib 100%
  • CRISPR 50%
  • NOD SCID Gamma Mouse 25%

• Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

  Manrique, I., Greil, R., Andel, J., Sormann, S., Hartmann, B. L., Podar, K., Egle, A., Petzer, A., Zojer, N., Gunsilius, E., Ruckser, R., Bozic, B., Schmitt, C. A., Machherndl-Spandl, S., Agis, H., Schreder, M., Wang, S.-Y., Willenbacher, W., Krauth, M.-T. & Tinchon, C. & 5 others, Fillitz, M., Melchardt, T., Knop, S., Paiva, B. & Ludwig, H., 2021, In: Blood. 138, Supplement 1, 1669.

  Research output: Journal article (peer-reviewed) › Journal article

  • Treatment Response Time 100%
  • Cytogenetics 16%

• Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

  Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021, In: Blood. 138, Supplement 1, 1598.

  Research output: Journal article (peer-reviewed) › Journal article

  • Cyclin-Dependent Kinase 100%
  • Serine 49%
  • mRNA Expression Level 49%
  • Cyclin-Dependent Kinase 9 49%
  • Threonine 49%

• Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

  Singer, J., Le, N.-S., Mattes, D., Klamminger, V., Hackner, K., Kolinsky, N., Scherb, M., Errhalt, P., Kreye, G., Pecherstorfer, M., Vallet, S. & Podar, K., 26 Aug 2021, In: Cancers. 13, 17, 4312.

  Research output: Journal article (peer-reviewed) › Journal article

  Open Access

  • Protein Antibody 100%
  12 Citations (Scopus)

• Highlights beim Multiplen Myelom

  Podar, K., 2021, 2 p.

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• JunB is a key regulator of multiple myeloma bone marrow angiogenesis

  Fan, F., Malvestiti, S., Vallet, S., Lind, J., Garcia-Manteiga, J. M., Morelli, E., Jiang, Q., Seckinger, A., Hose, D., Goldschmidt, H., Stadlbauer, A., Sun, C., Mei, H., Pecherstorfer, M., Bakiri, L., Wagner, E. F., Tonon, G., Sattler, M., Hu, Y. & Tassone, P. & 2 others, Jaeger, D. & Podar, K., Dec 2021, In: Leukemia. 35, 12, p. 3509-3525 17 p.

  Research output: Journal article (peer-reviewed) › Journal article

  Open Access

  • Multiple Myeloma 100%
  • Angiogenesis 100%
  • Myeloma Cell 25%
  • Angiogenic Factor 25%
  • Mouse Model 20%
  22 Citations (Scopus)

• Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma

  Pozzi, S., Bari, A., Pecherstorfer, M. & Vallet, S., 01 Oct 2021, In: Cancers. 13, 19, 4978.

  Research output: Journal article (peer-reviewed) › Review article

  Open Access

  • Eye Toxicity 100%
  • Belantamab Mafodotin 100%
  • Erythropoietin 100%
  10 Citations (Scopus)

• OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity: 18th International Myeloma Workshop, 08.-11.09.2021, Vienna, Austria

  Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Zwickl-Traxler, E., Fan, F., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E., Sattler, M., Pecherstorfer, M. & Podar, K., 2021, In: Clinical Lymphoma, Myeloma and Leukemia. 21, p. S19-S20

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Oncogene C Myc 100%
  • Trametinib 100%
  • Transcription Factors 75%
  • Protein Catabolism 50%
  • Cell Proliferation 50%

• P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies: 18th International Myeloma Workshop, 08.-11.09.2021, Vienna, Austria

  Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021, In: Clinical Lymphoma, Myeloma and Leukemia. 21, p. S83-S84

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • RNA 100%
  • Mdm2 100%
  • IRF4 100%
  • Small Interfering RNA 66%
  • Cell Survival 66%

• Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

  Podar, K. & Leleu, X., 01 Oct 2021, In: Cancers. 13, 20, 5154.

  Research output: Journal article (peer-reviewed) › Review article

  Open Access

  • Neoplasm 100%
  • Multiple Myeloma 100%
  • B Cell Maturation Antigen 100%
  • Immunotherapy 100%
  • COVID-19 50%
  38 Citations (Scopus)

• The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology

  Fan, F. & Podar, K., 02 May 2021, In: Cancers. 13, 10, 2326.

  Research output: Journal article (peer-reviewed) › Review article

  Open Access

  • Pathophysiology 100%
  • Cytotechnology 100%
  • Multiple Myeloma 100%
  • Activator Protein 1 100%
  • Immunoglobulin Producing Cell 100%
  25 Citations (Scopus)

• Time to best response correlates with outcome in the randomized comparison between KRD and KTD followed by K maintenance or observation (AGMT-MM02 TRIAL): EHA 2021 Virtual Congress, 9.-17.6.2021, Online

  Ludwig, H., Melchardt, T., Sormann, S., Schreder, M., Andel, J., Hartmann, B., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Zojer, N., Ruckser, R., Bozic, B., Krauth, M. T., Petzer, A., Schmitt, C. A., Machherndl-Spandl, S. & Agis, H. & 5 others, Fillitz, M., Pönisch, W., Knop, S., Paiva, B. & Greil, R., 2021, p. 325729; EP971.

  Research output: Contribution to conference › Poster at a conference
• 2020

  Carfilzomib in combination with either Rd or Td overcomes the negative impact of HR cytogenetics in NDMM. Interim efficacy analysis of combined data of KRd vs. KTd followed by K maintenance or control: 25th Congress of the European Hematology Association (EHA), online

  Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B. L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C. A., Machherndl-Spandl, S., Agis, H., Fillitz, M. & Paiva, B. & 1 others, Greil, R., 2020.

  Research output: Contribution to conference › Poster at a conference

• Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy: Abstractband für die Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts

  Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E. F., Sattler, M., Pecherstorfer, M. & Podar, K., 2020, In: Oncology Research and Treatment. 43, Suppl. 4, p. 92

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  Open Access

• Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

  Manrique, I., Greil, R., Andel, J., Sormann, S., Hartmann, B. L., Podar, K., Egle, A., Petzer, A., Zojer, N., Ruckser, R., Bozic, B., Schmitt, C. A., Machherndl-Spandl, S., Agis, H., Schreder, M., Krauth, M.-T., Tinchon, C., Fillitz, M., Melchardt, T. & Paiva, B. & 1 others, Ludwig, H., 2020, In: Blood. 136, Supplement 1, p. 29-30 2 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Natural Killer Cell 100%
  • Immunocompetent Cell 100%
  • Immunophenotyping 100%
  • Immunity 100%
  • Bone Marrow 100%

• Kombinationstherapien in der Behandlung urogenitaler Tumoren

  Vallet, S., 2020

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• Multiples Myelom 2020: Was für Patienten erreicht wurde

  Podar, K., 2020, 4 p.

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

  Ludwig, H., Melchardt, T., Andel, J., Gunsilius, E., Sormann, S., Hinke, A., Hartmann, B. L., Podar, K., Willenbacher, W., Egle, A., Petzer, A., Zojer, N., Wöll, E., Ruckser, R., Bozic, B., Schmitt, C. A., Machherndl-Spandl, S., Krauth, M.-T., Schreder, M. & Agis, H. & 3 others, Tinchon, C., Fillitz, M. & Greil, R., 2020, In: Blood. 136, Supplement 1, p. 27-29 3 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Multiple Myeloma 100%
  • Carfilzomib 100%
  • Quality of Life 100%
  • Population 75%
  • Maintenance Therapy 25%

• Stellenwert der autologen Stammzelltransplantation beim multiplen Myelom

  Podar, K., 2020, 4 p.

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)
• 2019

  Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02): American Society of Hematology, 61th Annual Meeting, scientific session

  Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B. L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C. A., Machherndl-Spandl, S., Agis, H., Paiva, B. & Greil, R., 2019, In: Blood. 134, Supplement_1, p. 696 1 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Americans 100%
  • Annuals 100%
  • Dexamethasone 100%
  • Cytogenetics 33%
  • Population 20%

• Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy: American Society of Hematology, 61th Annual Meeting, scientific session

  Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Sattler, M., Bakiri, L., Wagner, E. F., Percherstorfer, M. & Podar, K., 2019, In: Blood. 134, Supplement_1, p. 4415 1 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Myc Protein 100%
  • Ligase 50%
  • G1/S Transition 50%
  • Doxycycline 45%

• Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy: 17th International Myeloma Workshop, Boston

  Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E. F., Sattler, M., Pecherstorfer, M. & Podar, K., 2019.

  Research output: Contribution to conference › Poster at a conference

• Emerging protein kinase inhibitors for the treatment of multiple myeloma

  Lind, J., Czernilofsky, F., Vallet, S. & Podar, K., 03 Jul 2019, In: Expert Opinion on Emerging Drugs. 24, 3, p. 133-152 20 p.

  Research output: Journal article (peer-reviewed) › Review article

  • Protein Kinase Inhibitor 100%
  • Bruton Tyrosine Kinase 16%
  22 Citations (Scopus)

• Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group: American Society of Hematology, 61th Annual Meeting, scientific session

  Pleyer, L., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Petzer, A., Schmitt, C. A., Vallet, S., Mandac, I., Geissler, K., Sperr, W. R., Leisch, M., Egle, A., Melchardt, T., Fusinato, J., Piringer, G. & Zebisch, A. & 4 others, Machherndl-Spandl, S., Wolf, D., Keil, F. & Greil, R., 2019, In: Blood. 134, Supplement_1, p. 3821 1 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Acute Myeloid Leukemia 100%
  • Myelodysplastic Syndrome 100%
  • Azacitidine 100%
  • Hypomethylating Agent 100%
  • Chronic Myelomonocytic Leukemia 100%

• Klinisch relevante Arzneimittelinteraktionen im Multiplen Myelom: Hämatologie im Wandel der Zeit, 28.-29.06.2019, Wien

  Podar, K., 2019.

  Research output: Contribution to conference › Oral presentation at a conference

• Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis: American Society of Hematology, 61th Annual Meeting, scientific session

  Fan, F., Malvestiti, S., Shen, Y., Morelli, E., Mishima, Y., Seckinger, A., Hose, D., Bakiri, L., Vallet, S., Sattler, M., Roccaro, A. M., Goldschmidt, H., Percherstorfer, M., Sun, C., Hu, Y., Wagner, E. F., Tassone, P., Ghobrial, I. M., Jaeger, D. & Podar, K., 2019, In: Blood. 134, Supplement_1, p. 4341 1 p.

  Research output: Journal article (peer-reviewed) › Conference contribution to journal

  • Angiogenesis 100%
  • Cell Clone 33%
  • TetR 23%
  • Angiogenic Factor 16%
  • Chromatin Immunoprecipitation 16%

• Multiples Myelom II: DGHO, OeGHO, SGMO & SGH 2019 (Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie), Berlin

  Podar, K., 2019.

  Research output: Contribution to conference › Invited talk/keynote at a conference

• Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

  Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F. & Kaminetzky, D. & 32 others, Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J.-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22 Aug 2019, In: New England Journal of Medicine. 381, 8, p. 727-738 12 p.

  Research output: Journal article (peer-reviewed) › Journal article

  Open Access

  • Nausea 100%
  • Alkylating Agent 100%
  • Exportin 1 100%
  476 Citations (Scopus)

• Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

  Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiss, A., Schulze-Bergkamen, H., Opferman, J. T., Cardone, M. H., Jäger, D. & Podar, K., 15 Feb 2019, In: Breast Cancer Research and Treatment. 173, 3, p. 585-596 12 p.

  Research output: Journal article (peer-reviewed) › Journal article

  • Blood Toxicity 100%
  • Triple Negative Breast Cancer 100%
  16 Citations (Scopus)

• Stellenwert der Autologen Stammzelltransplantation beim Multiplen Myelom: 9. Niederösterreichischer Onkologietag, Krems

  Podar, K., 2019.

  Research output: Contribution to conference › Oral presentation at a conference

• Targeting transcription factors for cancer therapy: evolving therapeutic strategies: 9. Niederösterreichischer Onkologietag, Krems

  Podar, K., 2019.

  Research output: Contribution to conference › Oral presentation at a conference

• Targeting transcription factors in multiple myeloma: evolving therapeutic strategies

  Li, S., Vallet, S., Sacco, A., Roccaro, A., Lentzsch, S. & Podar, K., 04 May 2019, In: Expert Opinion on Investigational Drugs. 28, 5, p. 445-462 18 p.

  Research output: Journal article (peer-reviewed) › Review article

  • Hormone Receptor 100%
  • Therapeutic Window 33%
  13 Citations (Scopus)
• 2018

  A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma

  Vallet, S., Hoyle, N. R., Kyle, R. A., Podar, K. & Pecherstorfer, M., 03 Oct 2018, In: Leukemia and Lymphoma. 59, 10, p. 2431-2438 8 p.

  Research output: Journal article (peer-reviewed) › Journal article

  • Disease Exacerbation 100%
  • Amino Terminal Sequence 100%
  • Collagen Type 1 100%
  • Multiple Myeloma 100%
  • Bone Turnover 100%
  11 Citations (Scopus)

• Checkpointblockade beim metastasierten Urothelkarzinom

  Vallet, S., 2018

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• Choosing an appropriate salvage therapy for a patient with multiple myeloma

  Podar, K., 22 Sept 2018, In: Expert Opinion on Pharmacotherapy. 19, 14, p. 1511-1516 6 p.

  Research output: Journal article (peer-reviewed) › Editorial

  Open Access
  1 Citation (Scopus)

• Immunmodulierende Medikamente bleiben essenzielle Basis der Therapie

  Podar, K., 2018

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• Multiple myeloma pathogenesis: The role of JunB in bone marrow angiogenesis: 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden

  Malvestiti, S., Fan, F., Bashari, H. M., Morelli, E., Seckinger, A., Hose, D., Goldschmidt, H., Zoernig, I., Bakiri, L., Sattler, M., Vallet, S., Pecherstorfer, M., Wagner, E. F., Tassone, P., Jaeger, D. & Podar, K., 2018, p. PS1282.

  Research output: Contribution to conference › Poster at a conference

• Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

  Vallet, S., Filzmoser, J.-M., Pecherstorfer, M. & Podar, K., Dec 2018, In: Pharmaceutics. 10, 4, 202.

  Research output: Journal article (peer-reviewed) › Review article

  Open Access

  • Multiple Myeloma 100%
  • Bone Disease 100%
  • Myeloma Bone Disease 100%
  • RANKL 100%
  • Denosumab 100%
  30 Citations (Scopus)

• Teamwork gegen Krebs

  Podar, K., 2018, 3 p.

  Research output: Other publication (non peer-reviewed) › Other publication (not peer-reviewed)

• The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

  Breitkreutz, I., Podar, K., Figueroa-Vazquez, V., Wilhelm, S., Hayden, P. J., Anderson, K. C. & Raab, M. S., 01 May 2018, In: Annals of Hematology. 97, 5, p. 839-849 11 p.

  Research output: Journal article (peer-reviewed) › Journal article

  • Regorafenib 100%
  • Idelalisib 10%
  • Raf Protein 10%
  8 Citations (Scopus)

• Therapiefortschritte – Hämato-Onkologie im Jahr 2018: Multiples Myelom: 8. Niederösterreichischer Onkologietag, Krems an der Donau

  Podar, K., 2018.

  Research output: Contribution to conference › Invited talk/keynote at a conference

• Transcription factors in multiple myeloma: new potential targets: 4th Multiple Myeloma and related malignancies, Bari, Italy

  Podar, K., 2018.

  Research output: Contribution to conference › Invited talk/keynote at a conference
• 2017

  Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

  Bhanot, H., Weisberg, E. L., Reddy, M. M., Nonami, A., Neuberg, D., Stone, R. M., Podar, K., Salgia, R., Griffin, J. D. & Sattler, M., 15 Sept 2017, In: Oncotarget. 8, 40, p. 67639-67650 12 p.

  Research output: Journal article (peer-reviewed) › Journal article

  Open Access

  • Phosphogluconate Dehydrogenase 100%
  • Reduced Nicotinamide Adenine Dinucleotide Phosphate 100%
  • Reprogramming 100%
  • Hexose Monophosphate Shunt 16%
  • Sirtuin 1 16%
  22 Citations (Scopus)

• Adoptive cell therapy in multiple Myeloma

  Vallet, S., Pecherstorfer, M. & Podar, K., 02 Dec 2017, In: Expert Opinion on Biological Therapy. 17, 12, p. 1511-1522 12 p.

  Research output: Journal article (peer-reviewed) › Review article

  • Multiple Myeloma 100%
  • Cell Therapy 100%
  • Immunotherapy 60%
  • Chimeric Antigen Receptor T-Cell 40%
  • Engineered Cell 40%
  10 Citations (Scopus)

• Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma

  Podar, K. & Pecherstorfer, M., 24 Jul 2017, In: Expert Opinion on Pharmacotherapy. 18, 11, p. 1061-1079 19 p.

  Research output: Journal article (peer-reviewed) › Review article

  • Drug Therapy 100%
  • Multiple Myeloma 100%
  • Neoplasm 11%
  • Diseases 11%
  • Immune Checkpoint Inhibitor 11%
  5 Citations (Scopus)

• Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial

  Rosenberger, F., Wiskemann, J., Vallet, S., Haag, G. M., Schembri, E., Jäger, D. & Grüllich, C., 01 Dec 2017, In: Supportive Care in Cancer. 25, 12, p. 3655-3664 10 p.

  Research output: Journal article (peer-reviewed) › Journal article

  • Tyrosine-Kinase Inhibitor 100%
  • Advanced Cancer 100%
  • Resistance Training 100%
  • Muscle Strength 75%
  • Renal Cell Carcinoma 50%
  7 Citations (Scopus)

• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma

  Podar, K. & Jager, D., 2017, In: Current Cancer Drug Targets. 17, 9, p. 782-805 24 p.

  Research output: Journal article (peer-reviewed) › Review article

  • Immunity 100%
  • Multiple Myeloma 100%
  • Bone Marrow Microenvironment 100%
  • Immunotherapy 100%
  • T Cell 27%
  17 Citations (Scopus)

• The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

  Fan, F., Bashari, M. H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., Sun, C., Hu, Y., Ball, C. R., Glimm, H., Sattler, M., Goldschmidt, H., Wagner, E. F., Tassone, P., Jaeger, D. & Podar, K., 01 Jul 2017, In: Leukemia. 31, 7, p. 1570-1581 12 p.

  Research output: Journal article (peer-reviewed) › Journal article

  • Transcription Factor JunB 100%
  • Transcription Factor AP 1 100%
  • Multiple Myeloma 100%
  • Drug Resistance 100%
  • Dexamethasone 100%
  58 Citations (Scopus)